Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study

Journal of Oncology Pharmacy Practice

Volumn 20, Issue 4, 2014, Pages 263-269

  Deauna Limayo, Delva ^a   Aljitawi, Omar S ^b   Ganguly, Siddhartha ^b   Abhyankar, Sunil ^b   Wick, Jo A ^c   McGuirk, Joseph P ^b  

^a NEVADA CANCER INSTITUTE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Aprepitant; Autologous hematopoietic stem cell transplant; Chemotherapy induced nausea and vomiting; Multiday palonosetron

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; DEXAMETHASONE; ISOQUINOLINE DERIVATIVE; MORPHOLINE DERIVATIVE; PALONOSETRON; QUINUCLIDINE DERIVATIVE;

ADULT; AGED; AUTOTRANSPLANTATION; CHEMICALLY INDUCED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NAUSEA; PILOT STUDY; QUALITY OF LIFE; VOMITING;

ADULT; AGED; ANTIEMETICS; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISOQUINOLINES; LYMPHOMA; MALE; MIDDLE AGED; MORPHOLINES; MULTIPLE MYELOMA; NAUSEA; PILOT PROJECTS; QUALITY OF LIFE; QUINUCLIDINES; TRANSPLANTATION, AUTOLOGOUS; VOMITING;

EID: 84905655973     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155213502103     Document Type: Article

References (15)

1. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109
2. Lopez-Jimenez J, Martin-Ballesteros E, Sureda A, et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: Results of a multicenter, observational study. Haematologica 2006; 91: 84-91
3. Abbott B, Ippoliti C, Hecth D, et al. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 2000; 25: 1279-1283
4. Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008; 107: 469-478
5. Hunt T, Gallagher S, Cullen M, et al. Evaluation of safety and pharmacokinetics of consecutive multipleday dosing of palonosetron in healthy subjects. J Clin Pharmacol 2005; 45: 589-596
6. Hesketh PJ. Understanding the pathobiology of chemotherapy- induced nausea and vomiting. Oncology 2004; 18(suppl 6): 9-14
7. Olver IN. Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting. J Clin Pract 2004; 58: 201-206
8. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74: 17-24
9. Shah AK, Hunt TL, Gallagher SC, et al. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 2005; 21: 595-601
10. Giralt SA, Mangan KF, Maziarz RT, et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 2011; 22: 939-946
11. Paul B, Trovato JA, Thompson J, et al. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010; 16: 45-51
12. Jordan K, Jahn F, Jahn P, et al. The NK-1 receptor antagonist aprepitant in high dose (HD) chemotherapy (HD melphalan and HD T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): Efficacy and safety of triple antiemetic combination. Bone Marrow Transplant. Epub ahead of print 13 September 2010. DOI: 10.1038/ bmt.2010.205
13. Musso M, Scalone R, Crescimanno A, et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 2010; 45: 123-127
14. Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw 2007; 5: 51-59
15. Fauser AA, Russ W and Bischoff M. Oral dolasetron mesylate (MDL73,147EF) for the control of emesis during fractionated total-body irradiation and high dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation. Support Care Cancer 1997; 5: 219-222.